vs
Apellis Pharmaceuticals, Inc.（APLS）与GRID DYNAMICS HOLDINGS, INC.（GDYN）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是GRID DYNAMICS HOLDINGS, INC.的1.9倍（$199.9M vs $104.1M），GRID DYNAMICS HOLDINGS, INC.净利率更高（-1.4% vs -29.5%，领先28.1%），GRID DYNAMICS HOLDINGS, INC.同比增速更快（3.7% vs -5.9%），过去两年GRID DYNAMICS HOLDINGS, INC.的营收复合增速更高（12.0% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Escape Dynamics Inc.是一家总部位于科罗拉多州的科技企业，活跃于2010年至2015年，核心业务方向是研发可单级入轨、依靠电磁驱动的可重复使用航天飞机，并推动该项目实现商业化落地。
APLS vs GDYN — 直观对比
营收规模更大
APLS
是对方的1.9倍
$104.1M
营收增速更快
GDYN
高出9.6%
-5.9%
净利率更高
GDYN
高出28.1%
-29.5%
两年增速更快
GDYN
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $104.1M |
| 净利润 | $-59.0M | $-1.5M |
| 毛利率 | — | 34.8% |
| 营业利润率 | -25.6% | 61.7% |
| 净利率 | -29.5% | -1.4% |
| 营收同比 | -5.9% | 3.7% |
| 净利润同比 | -62.2% | -150.6% |
| 每股收益（稀释后） | $-0.40 | $-0.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSGDYN
| Q1 26 | — | $104.1M | ||
| Q4 25 | $199.9M | $106.2M | ||
| Q3 25 | $458.6M | $104.2M | ||
| Q2 25 | $178.5M | $101.1M | ||
| Q1 25 | $166.8M | $100.4M | ||
| Q4 24 | $212.5M | $100.3M | ||
| Q3 24 | $196.8M | $87.4M | ||
| Q2 24 | $199.7M | $83.0M |
净利润APLSGDYN
| Q1 26 | — | $-1.5M | ||
| Q4 25 | $-59.0M | $306.0K | ||
| Q3 25 | $215.7M | $1.2M | ||
| Q2 25 | $-42.2M | $5.3M | ||
| Q1 25 | $-92.2M | $2.9M | ||
| Q4 24 | $-36.4M | $4.5M | ||
| Q3 24 | $-57.4M | $4.3M | ||
| Q2 24 | $-37.7M | $-817.0K |
毛利率APLSGDYN
| Q1 26 | — | 34.8% | ||
| Q4 25 | — | 34.0% | ||
| Q3 25 | — | 33.3% | ||
| Q2 25 | — | 34.1% | ||
| Q1 25 | — | 36.8% | ||
| Q4 24 | — | 36.9% | ||
| Q3 24 | — | 37.4% | ||
| Q2 24 | — | 35.6% |
营业利润率APLSGDYN
| Q1 26 | — | 61.7% | ||
| Q4 25 | -25.6% | 0.5% | ||
| Q3 25 | 48.7% | -0.2% | ||
| Q2 25 | -18.6% | -0.1% | ||
| Q1 25 | -50.0% | -2.0% | ||
| Q4 24 | -12.3% | 1.3% | ||
| Q3 24 | -24.0% | 2.4% | ||
| Q2 24 | -14.7% | 0.0% |
净利率APLSGDYN
| Q1 26 | — | -1.4% | ||
| Q4 25 | -29.5% | 0.3% | ||
| Q3 25 | 47.0% | 1.1% | ||
| Q2 25 | -23.6% | 5.2% | ||
| Q1 25 | -55.3% | 2.9% | ||
| Q4 24 | -17.1% | 4.5% | ||
| Q3 24 | -29.2% | 4.9% | ||
| Q2 24 | -18.9% | -1.0% |
每股收益（稀释后）APLSGDYN
| Q1 26 | — | $-0.02 | ||
| Q4 25 | $-0.40 | $0.01 | ||
| Q3 25 | $1.67 | $0.01 | ||
| Q2 25 | $-0.33 | $0.06 | ||
| Q1 25 | $-0.74 | $0.03 | ||
| Q4 24 | $-0.30 | $0.06 | ||
| Q3 24 | $-0.46 | $0.05 | ||
| Q2 24 | $-0.30 | $-0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $327.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $530.1M |
| 总资产 | $1.1B | $605.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSGDYN
| Q1 26 | — | $327.5M | ||
| Q4 25 | $466.2M | $342.1M | ||
| Q3 25 | $479.2M | $338.6M | ||
| Q2 25 | $370.0M | $336.8M | ||
| Q1 25 | $358.4M | $325.5M | ||
| Q4 24 | $411.3M | $334.7M | ||
| Q3 24 | $396.9M | $231.3M | ||
| Q2 24 | $360.1M | $256.0M |
股东权益APLSGDYN
| Q1 26 | — | $530.1M | ||
| Q4 25 | $370.1M | $542.1M | ||
| Q3 25 | $401.2M | $537.7M | ||
| Q2 25 | $156.3M | $532.2M | ||
| Q1 25 | $164.2M | $517.4M | ||
| Q4 24 | $228.5M | $517.8M | ||
| Q3 24 | $237.1M | $400.2M | ||
| Q2 24 | $264.3M | $388.4M |
总资产APLSGDYN
| Q1 26 | — | $605.0M | ||
| Q4 25 | $1.1B | $612.9M | ||
| Q3 25 | $1.1B | $613.2M | ||
| Q2 25 | $821.4M | $608.9M | ||
| Q1 25 | $807.3M | $590.9M | ||
| Q4 24 | $885.1M | $592.2M | ||
| Q3 24 | $901.9M | $477.3M | ||
| Q2 24 | $904.5M | $443.6M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSGDYN
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | $9.9M | ||
| Q3 25 | $108.5M | $7.0M | ||
| Q2 25 | $4.4M | $14.4M | ||
| Q1 25 | $-53.4M | $9.4M | ||
| Q4 24 | $19.4M | $7.1M | ||
| Q3 24 | $34.1M | $9.2M | ||
| Q2 24 | $-8.3M | $10.7M |
自由现金流APLSGDYN
| Q1 26 | — | — | ||
| Q4 25 | $-14.3M | $6.1M | ||
| Q3 25 | $108.3M | $2.9M | ||
| Q2 25 | $4.4M | $10.2M | ||
| Q1 25 | $-53.4M | $6.0M | ||
| Q4 24 | $19.3M | $4.4M | ||
| Q3 24 | — | $5.9M | ||
| Q2 24 | $-8.4M | $8.0M |
自由现金流率APLSGDYN
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | 5.7% | ||
| Q3 25 | 23.6% | 2.8% | ||
| Q2 25 | 2.5% | 10.1% | ||
| Q1 25 | -32.0% | 6.0% | ||
| Q4 24 | 9.1% | 4.4% | ||
| Q3 24 | — | 6.8% | ||
| Q2 24 | -4.2% | 9.7% |
资本支出强度APLSGDYN
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 3.6% | ||
| Q3 25 | 0.0% | 3.9% | ||
| Q2 25 | 0.0% | 4.1% | ||
| Q1 25 | 0.0% | 3.3% | ||
| Q4 24 | 0.0% | 2.6% | ||
| Q3 24 | 0.0% | 3.7% | ||
| Q2 24 | 0.0% | 3.2% |
现金转化率APLSGDYN
| Q1 26 | — | — | ||
| Q4 25 | — | 32.34× | ||
| Q3 25 | 0.50× | 5.92× | ||
| Q2 25 | — | 2.73× | ||
| Q1 25 | — | 3.21× | ||
| Q4 24 | — | 1.56× | ||
| Q3 24 | — | 2.15× | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
GDYN
暂无分部数据
